Autolus is a biopharmaceutical company focused on T-cell programming and manufacturing technology.
Autolus has raised $350.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in February 2024.
Autolus's investors include Cormorant Asset Management, Blackstone Group, Google Ventures, 4BIO Capital, Nextech Invest.
Autolus is headquartered in London, United Kingdom.
Autolus is a biopharmaceutical company focused on T-cell programming and manufacturing technology.
Autolus is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Autolus — Funding & Investors." VCBacked, February 8, 2024, https://www.vcbacked.co/company/autolus. Accessed September 30, 2026.
VCBacked. (2024). Autolus — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/autolus
{{cite web |title=Autolus — Funding & Investors |url=https://www.vcbacked.co/company/autolus |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated